The IGH/CCND1 product consists of probes, labelled in green, covering the Constant, J, D and Variable segments of the IGH gene, and CCND1 probes labelled in red. The CCND1 probe mix contains a 267kb probe centromeric to CCND1 gene, covering the region between the D11S1100 and the D11S4095 markers, and a second 223kb probe covering the telomeric end of CCND1 gene.
Although translocations involving IGH and CCND1 (BCL1) were initially reported in B-CLL patients, the rearrangement is now considered to be a hallmark of mantle cell lymphoma (MCL).
Reciprocal translocations involving the IGH and CCND1 (previously known as BCL1) loci, t(11;14)(q13;q32), were frequently reported in B-CLL patients1. The involvement of the CCND1 (Cyclin D1) gene was initially reported from a cloning study looking at the breakpoints of the translocation. However, it is likely that the initial diagnosis on the samples used for the study should have been MCL. The IGH/CCND1 probe for detection of t(11;14) has been recommended by the British Committee for Standards in Haematology to enable atypical B-CLL patients to be distinguished from possible MCL patients2.
The quality and reproducibility of results using the CytoCell kit has been vital in accurately detecting co-deletions in our glioma investigations. We now have a cost-effective test that we can rely on that is also easy to use and interpret. We've been consistently impressed with this kit - not to mention the support offered by OGT's customer service, and have completely transitioned over to CytoCell probes.
Gavin Cuthbert, FRCPath
Head of Cancer Cytogenetics, Northern Genetics Service, Newcastle, UK
Visit USA site
Visit Canada site
